Inhibikase Therapeutics is based in Atlanta, Georgia. It has raised $345M in total funding. Latest round: Growth.
Inhibikase Therapeutics funding overview
Inhibikase Therapeutics is based in Atlanta, Georgia. Inhibikase Therapeutics has raised $345M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Growth announced in May 2024. The round record for Inhibikase Therapeutics runs through 2024; nothing later has been disclosed.
Inhibikase Therapeutics at a glance
Total raised
$345M
Latest round
Growth
Latest round date
May 2024
Headquarters
Atlanta, Georgia
Frequently asked about Inhibikase Therapeutics funding
How much has Inhibikase Therapeutics raised?
Inhibikase Therapeutics has raised $345M in total disclosed funding across the rounds on record.
Who has invested in Inhibikase Therapeutics?
No investors are named on the public record for Inhibikase Therapeutics yet.
What was the latest Inhibikase Therapeutics funding round?
The most recent disclosed round is a Growth, announced in May 2024.
Where is Inhibikase Therapeutics based?
Inhibikase Therapeutics is based in Atlanta, Georgia.
When did Inhibikase Therapeutics last raise?
The last disclosed Inhibikase Therapeutics round closed in May 2024 at Growth.
Inhibikase Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Atlanta below to benchmark round size and investor mix.
